Withdrawal of rimonabant - Walking the tightrope of 21st century pharmaceutical regulation?

Current Drug Safety

Volumn 4, Issue 1, 2009, Pages 2-4

  Taylor, David ^a,b  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; PLACEBO; RIMONABANT; ANTIOBESITY AGENT; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

AGGRESSION; ANXIETY; CLINICAL TRIAL; DEPRESSION; DIZZINESS; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG CONTROL; DRUG EFFICACY; DRUG LEGISLATION; DRUG MARKETING; DRUG QUALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; INSOMNIA; LEGAL ASPECT; LICENSING; MOOD DISORDER; NAUSEA; OBESITY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PSYCHOPATHY; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SUICIDAL IDEATION; ARTICLE; EUROPE; GOVERNMENT; METHODOLOGY; RISK ASSESSMENT;

ANTI-OBESITY AGENTS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; EUROPE; GOVERNMENT AGENCIES; HUMANS; PIPERIDINES; PYRAZOLES; RISK ASSESSMENT;

EID: 63249114370     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488609787354396     Document Type: Review

References (17)

1. MHRA. Europe wide suspension of Marketing Authorisation for Acomplia (rimonabant). http://www.mhra.gov.uk/NewsCentre/CON028544. 2008.
2. European Medicines Agency. Rimonabant approval - background information on the procedure. http://www.emea.europa.eu/humandocs/PDFs/EPAR/acomplia/ H-666-en7.pdf. 2008.
3. Howlett AC, Breivogel CS, Childers S, et al. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 2004; 47(Suppl 1): 345-8.
4. Fernandez JR, Allison DB. Rimonabant Sanofi-Synthelabo. Curr Opin Investig Drugs 2004; 5: 430-5.
5. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-97.
6. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121-34.
7. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006; 295: 761-75.
8. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006; 368: 1660-72.
9. Nissen SE, Nicholls SJ, Wolski K, et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 2008; 299: 1547-60.
10. Rosenstock J, Hollander P, Chevalier S, Iranmanesh A. SERENADE: The Study Evaluating Rimonabant Efficacy in Drug-Naive Diabetic Patients: Effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes. Diabetes Care 2008; 31: 2169-76.
11. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-70.
12. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007; 370: 1706-13.
13. European Medicines Agency. Rimonabant approval. Procedural steps taken and scientific information after the authorisation. http://emea.europa.ec/humandocs/PDFs/EPAR/Acomplia/H-666-en8.pdf. 2008.
14. European Medicines Agency. Acomplia - Scientific Discussion. http://www.emea.europa.eu. 2008.
15. MHRA. Drug Safety Advice. Rimonabant (Acomplia). Drug Saf Update 2008; 1: 2-4.
16. European Medicines Agency. The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia. http://www.emea.europa.eu/humandocs/PDFs/EPAR/acomplia/53777708en.pdf. 2008.
17. FDA. NDA 21-888. Zimulti (rimonabant) tablets 20 mg. Sanofi Aventis Advisory Committee June 13 2007. http://www.fda.gov/. 2008.